Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Low plasma leptin in cognitively impaired ADNI subjects: gender differences and diagnostic and therapeutic potential.

Johnston JM, Hu WT, Fardo DW, Greco SJ, Perry G, Montine TJ, Trojanowski JQ, Shaw LM, Ashford JW, Tezapsidis N; Alzheimer’s Disease Neuroimaging Initiative.

Curr Alzheimer Res. 2014 Feb;11(2):165-74.

2.

ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.

Apostolova LG, Hwang KS, Kohannim O, Avila D, Elashoff D, Jack CR Jr, Shaw L, Trojanowski JQ, Weiner MW, Thompson PM; Alzheimer's Disease Neuroimaging Initiative.

Neuroimage Clin. 2014 Jan 4;4:461-72. doi: 10.1016/j.nicl.2013.12.012. eCollection 2014.

3.

Cerebrospinal fluid cortisol and clinical disease progression in MCI and dementia of Alzheimer's type.

Popp J, Wolfsgruber S, Heuser I, Peters O, Hüll M, Schröder J, Möller HJ, Lewczuk P, Schneider A, Jahn H, Luckhaus C, Perneczky R, Frölich L, Wagner M, Maier W, Wiltfang J, Kornhuber J, Jessen F.

Neurobiol Aging. 2015 Feb;36(2):601-7. doi: 10.1016/j.neurobiolaging.2014.10.031. Epub 2014 Oct 31.

PMID:
25435336
4.

Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition.

Toledo JB, Weiner MW, Wolk DA, Da X, Chen K, Arnold SE, Jagust W, Jack C, Reiman EM, Davatzikos C, Shaw LM, Trojanowski JQ; Alzheimer’s Disease Neuroimaging Initiative.

Acta Neuropathol Commun. 2014 Mar 6;2:26. doi: 10.1186/2051-5960-2-26.

5.

Transthyretin decrease in plasma of MCI and AD patients: investigation of mechanisms for disease modulation.

Ribeiro CA, Santana I, Oliveira C, Baldeiras I, Moreira J, Saraiva MJ, Cardoso I.

Curr Alzheimer Res. 2012 Oct;9(8):881-9.

PMID:
22698061
6.

Biomarkers for Early Diagnostic of Mild Cognitive Impairment in Type-2 Diabetes Patients: A Multicentre, Retrospective, Nested Case-Control Study.

Xu ZP, Yang SL, Zhao S, Zheng CH, Li HH, Zhang Y, Huang RX, Li MZ, Gao Y, Zhang SJ, Zhan PY, Zhang LF, Deng L, Wei S, Liu YC, Ye JW, Ren HJ, Li N, Kong CX, Wang X, Fang L, Zhou QZ, Jiang HW, Li JR, Wang Q, Ke D, Liu GP, Wang JZ.

EBioMedicine. 2016 Feb 6;5:105-13. doi: 10.1016/j.ebiom.2016.02.014. eCollection 2016 Mar.

7.

Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.

Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060.

PMID:
25162367
8.

Integration and relative value of biomarkers for prediction of MCI to AD progression: spatial patterns of brain atrophy, cognitive scores, APOE genotype and CSF biomarkers.

Da X, Toledo JB, Zee J, Wolk DA, Xie SX, Ou Y, Shacklett A, Parmpi P, Shaw L, Trojanowski JQ, Davatzikos C; Alzheimer's Neuroimaging Initiative.

Neuroimage Clin. 2013 Nov 28;4:164-73. doi: 10.1016/j.nicl.2013.11.010. eCollection 2014.

9.

Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease.

Soares HD, Potter WZ, Pickering E, Kuhn M, Immermann FW, Shera DM, Ferm M, Dean RA, Simon AJ, Swenson F, Siuciak JA, Kaplow J, Thambisetty M, Zagouras P, Koroshetz WJ, Wan HI, Trojanowski JQ, Shaw LM; Biomarkers Consortium Alzheimer's Disease Plasma Proteomics Project.

Arch Neurol. 2012 Oct;69(10):1310-7.

10.

Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI) plasma proteome dataset.

Johnstone D, Milward EA, Berretta R, Moscato P; Alzheimer's Disease Neuroimaging Initiative.

PLoS One. 2012;7(4):e34341. doi: 10.1371/journal.pone.0034341. Epub 2012 Apr 2.

11.

Prognostic classification of mild cognitive impairment and Alzheimer's disease: MRI independent component analysis.

Willette AA, Calhoun VD, Egan JM, Kapogiannis D; Alzheimer׳s Disease Neuroimaging Initiative.

Psychiatry Res. 2014 Nov 30;224(2):81-8. doi: 10.1016/j.pscychresns.2014.08.005. Epub 2014 Aug 17.

12.

Decreased levels of circulating adiponectin in mild cognitive impairment and Alzheimer's disease.

Teixeira AL, Diniz BS, Campos AC, Miranda AS, Rocha NP, Talib LL, Gattaz WF, Forlenza OV.

Neuromolecular Med. 2013 Mar;15(1):115-21. doi: 10.1007/s12017-012-8201-2. Epub 2012 Sep 28.

PMID:
23055000
13.

The relationship of plasma Aβ levels to dementia in aging individuals with mild cognitive impairment.

Fei M, Jianghua W, Rujuan M, Wei Z, Qian W.

J Neurol Sci. 2011 Jun 15;305(1-2):92-6. doi: 10.1016/j.jns.2011.03.005. Epub 2011 Mar 26.

PMID:
21440911
14.

α-Synuclein in cerebrospinal fluid of Alzheimer's disease and mild cognitive impairment.

Korff A, Liu C, Ginghina C, Shi M, Zhang J; Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. 2013;36(4):679-88. doi: 10.3233/JAD-130458.

15.

Risk Stratification Using Cerebrospinal Fluid Biomarkers in Patients with Mild Cognitive Impairment: An Exploratory Analysis.

Michaud TL, Kane RL, McCarten JR, Gaugler JE, Nyman JA, Kuntz KM; Alzheimer's Disease Neuroimaging Initiative.

J Alzheimers Dis. 2015;47(3):729-40. doi: 10.3233/JAD-150066.

PMID:
26401707
16.

Plasminogen activator inhibitor-1 as an early potential diagnostic marker for Alzheimer's disease.

Oh J, Lee HJ, Song JH, Park SI, Kim H.

Exp Gerontol. 2014 Dec;60:87-91. doi: 10.1016/j.exger.2014.10.004. Epub 2014 Oct 8.

PMID:
25304332
17.

Does serum uric acid act as a modulator of cerebrospinal fluid Alzheimer's disease biomarker related cognitive decline?

Ye BS, Lee WW, Ham JH, Lee JJ, Lee PH, Sohn YH; Alzheimer's Disease Neuroimaging Initiative.

Eur J Neurol. 2016 May;23(5):948-57. doi: 10.1111/ene.12969. Epub 2016 Feb 24.

PMID:
26917248
18.

Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL).

Ellis KA, Szoeke C, Bush AI, Darby D, Graham PL, Lautenschlager NT, Macaulay SL, Martins RN, Maruff P, Masters CL, McBride SJ, Pike KE, Rainey-Smith SR, Rembach A, Robertson J, Rowe CC, Savage G, Villemagne VL, Woodward M, Wilson W, Zhang P, Ames D; AIBL Research Group.

Int Psychogeriatr. 2014 Apr;26(4):543-54. doi: 10.1017/S1041610213001956. Epub 2013 Nov 20.

PMID:
24252258
19.

Plasma protein profiling of mild cognitive impairment and Alzheimer's disease across two independent cohorts.

Muenchhoff J, Poljak A, Song F, Raftery M, Brodaty H, Duncan M, McEvoy M, Attia J, Schofield PW, Sachdev PS.

J Alzheimers Dis. 2015;43(4):1355-73. doi: 10.3233/JAD-141266.

PMID:
25159666
20.

APOE ε4 specific imbalance of arachidonic acid and docosahexaenoic acid in serum phospholipids identifies individuals with preclinical Mild Cognitive Impairment/Alzheimer's Disease.

Abdullah L, Evans JE, Emmerich T, Crynen G, Shackleton B, Keegan AP, Luis C, Tai L, LaDu MJ, Mullan M, Crawford F, Bachmeier C.

Aging (Albany NY). 2017 Mar 23;9(3):964-985. doi: 10.18632/aging.101203.

Supplemental Content

Support Center